
|Videos|June 17, 2014
Charles M. Perou, PhD, Discusses Genomic Signatures and Dual HER2-Targeting in Breast Cancer
Charles M. Perou, PhD, professor of genetics, pathology & laboratory medicine, UNC Lineberger Comprehensive Cancer Center, discusses a trial (CALGB 40601) presented at the 2014 ASCO Annual Meeting.
Advertisement
Charles M. Perou, PhD, professor of genetics, pathology & laboratory medicine, UNC Lineberger Comprehensive Cancer Center, discusses a trial (CALGB 40601) presented at the 2014 ASCO Annual Meeting that analyzed gene expression signatures in patients with HER2-positive breast cancer treated with weekly paclitaxel and trastuzumab with or without lapatinib.
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
New CKD Outcome Set Tells Pharmacists What to Measure
2
State Pharmacy Boards Must Step Up Against Illegal Retatrutide
3
The PBM Reform Clock Is Running to 2028—Here's What Independent Pharmacies Should Do
4
GLP-1s and the HCM–Sleep Apnea–Obesity Connection
5


































































































